CRIF1-CDK2 Interface Inhibitors Enhance Taxol Inhibition of the Lethal Triple-Negative Breast Cancer

CRIF1–CDK2 Interface Inhibitors: An Unprecedented Strategy for Modulation of Cell Radiosensitivity

(2019) Qian Ran et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

CRIF1 as a potential target to improve the radiosensitivity of osteosarcoma

(2019) Qian Ran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy

(2018) Christopher C. Mills et al.   CANCER RESEARCH

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

(2018) Juan Jin et al.   NEOPLASIA

MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer

(2016) Madeleine J. Oudin et al.   MOLECULAR CANCER THERAPEUTICS

Triple-negative breast cancer: is there a treatment on the horizon?

(2016) Hui Yao et al.   Oncotarget

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of MCF10A as a Reliable Model for Normal Human Mammary Epithelial Cells

(2015) Ying Qu et al.   PLoS One

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells

(2014) Jian Kang et al.   BMC CANCER

CDK2-AP1 inhibits growth of breast cancer cells by regulating cell cycle and increasing docetaxel sensitivity in vivo and in vitro

(2014) Xiangming He et al.   Cancer Cell International

How Taxol/paclitaxel kills cancer cells

(2014) Beth A. Weaver   MOLECULAR BIOLOGY OF THE CELL

CRIF1 Interacting with CDK2 Regulates Bone Marrow Microenvironment-Induced G0/G1 Arrest of Leukemia Cells

(2014) Qian Ran et al.   PLoS One

Anti-proliferative actions of N′-desmethylsorafenib in human breast cancer cells

(2013) Pei H. Cui et al.   BIOCHEMICAL PHARMACOLOGY

Signaling through cyclin D-dependent kinases

(2013) Y J Choi et al.   ONCOGENE

Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes

(2011) Antony S. Tin et al.   ANTI-CANCER DRUGS

Triple-negative breast cancer--current status and future directions

(2009) O. Gluz et al.   ANNALS OF ONCOLOGY